Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : APL-1702
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Recipient : Asieris Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
Brand Name : Cevira
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 20, 2023
Lead Product(s) : APL-1702
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Recipient : Asieris Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?